Open Access<p>Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)</p>
Author(s) -
Vito Lorusso,
Anna Lo Russo,
Francesco Giotta,
Paolo Codega
Publication year - 2020
Publication title -
core evidence
Language(s) - English
Resource type - Journals
eISSN - 1555-175X
pISSN - 1555-1741
DOI - 10.2147/ce.s203634
Subject(s) - palonosetron , chemotherapy induced nausea and vomiting , antiemetic , medicine , aprepitant , nausea , oncology , pharmacology , anesthesia
Antineoplastic drugs may induce several side effects, including chemotherapy-induced nausea and vomiting (CINV). Two neurotransmitters play a central role in mediating the emetic response: serotonin acting on the 5HT3 receptor and the substance P targeting the NK1 receptor. Indeed, a combination of a 5HT3 receptor antagonist (5HT3-RA) and a NK1 receptor antagonist (NK1-RA) together with dexamethasone has been shown to be very effective. In fact, this combination is actually widely used and recommended for CINV prophylaxis for highly emetogenic cisplatin-based adriamycin/cyclophosphamide (AC) and carboplatin-based regimens. NEPA (netupitant/palonosetron) is the only fixed combination antiemetic available and it is composed by the long-lasting second-generation 5HT3-RA palonosetron and the highly selective NK1-RA netupitant.